Todd Harris - Jun 13, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Jun 13, 2023
Transactions value $
-$286,292
Form type
4
Date filed
6/15/2023, 09:00 PM
Previous filing
Apr 5, 2023
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $17.8K +7.93K +0.47% $2.25* 1.71M Jun 13, 2023 Direct
transaction TYRA Common Stock Sale -$127K -7.93K -0.46% $16.00 1.7M Jun 13, 2023 Direct F1, F2
transaction TYRA Common Stock Options Exercise $28.7K +12.8K +0.75% $2.25* 1.71M Jun 15, 2023 Direct
transaction TYRA Common Stock Sale -$206K -12.8K -0.75% $16.13 1.7M Jun 15, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -7.93K -1.99% $0.00 390K Jun 13, 2023 Common Stock 7.93K $2.25 Direct F4
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -12.8K -3.28% $0.00 377K Jun 15, 2023 Common Stock 12.8K $2.25 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.05. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.60. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.